Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | YWHAG | P61981 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7423042 | 0.94 | GAA (0.51) | ALDH1A1GAAGFERHSP90AB1GPR35 | |
| SCHEMBL286994 | 0.88 | ALDH1A1 (0.59) | ALDH1A1GAAGFERHSP90AB1GPR35 | |
| SCHEMBL31170840 | 0.88 | ALDH1A1 (0.59) | ALDH1A1GAAGFERHSP90AB1GPR35 | |
| SCHEMBL4029398 | 0.85 | LMNA (0.49) | ALDH1A1GAAGPR35SNCAMAPT | |
| SCHEMBL4992802 | 0.85 | ALDH1A1 (0.52) | ALDH1A1GAAGFERHSP90AB1PDGFRB | |
| SCHEMBL5465423 | 0.85 | PDGFRB (0.53) | ALDH1A1GAAGFERHSP90AB1PDGFRB | |
| SCHEMBL2593349 | 0.84 | CYP1A2 (0.50) | ALDH1A1GAAGFERPDGFRBFGFR1 | |
| SCHEMBL4131823 | 0.84 | ATM (0.47) | ALDH1A1GAAGFERHSP90AB1PDGFRB | |
| SCHEMBL6209939 | 0.84 | ALDH1A1 (0.61) | ALDH1A1GAAGFERHSP90AB1PDGFRB | |
| SCHEMBL3726108 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAAGFERHSP90AB1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| EP-4071147-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | Lg Chem, Ltd. (KR) | 2022-10-12 | — | — | EP | disclosed |
| CN-114846013-A | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2022-08-02 | — | — | CN | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| WO-2021133035-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2021-07-01 | — | — | WO | disclosed |
| WO-2018138362-A1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
| EP-2986600-B1 | SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-05 | — | — | EP | disclosed |
| CN-1483024-A | Vla-4 inhibitors | ��һ��������ҩ��ʽ���� | 2004-03-17 | — | — | CN | disclosed |
| EP-1144393-B1 | BENZOXAZOLE DERIVATIVES FOR USE AS INTEGRIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003030889-A1 | PARA-AMINO BENZOIC ACIDS AS INTEGRIN ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1144393-A3 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITOR | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| US-6441012-B1 | BENZOXAZOLE OR BENZTHIAZOLE DERIVATIVES FOR INHIBITING THE INTERACTION BETWEEN CELLULAR ADHESION MOLECULES AND/OR FIBRONECTIN AND THE INTERGRIN RECEPTOR | ASTRAZENECA AB (SE) | 2002-08-27 | — | — | US | disclosed |
| EP-1144393-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITOR | AstraZeneca AB (SE) | 2001-10-17 | — | — | EP | disclosed |
| EP-1133484-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | AstraZeneca AB (SE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000005223-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-03 | — | — | WO | disclosed |
| WO-2000005224-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITOR | ASTRAZENECA AB (SE) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | ALDH1A1 118/4885GAA 839/4885GFER 3887/4885 |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | DGAT2, DGAT1, PLAAT2 | ALDH1A1 480/4885GAA 343/4885GFER 1159/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | ALDH1A1 597/4885GAA 791/4885GFER 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.